Reprint

Pediatric Cancers

Edited by
October 2023
456 pages
  • ISBN978-3-0365-9024-0 (Hardback)
  • ISBN978-3-0365-9025-7 (PDF)

This book is a reprint of the Special Issue Pediatric Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Childhood cancer or pediatric cancer is one of the leading causes of death among children. Treatment strategies for pediatric cancers include chemotherapy, surgery, radiation, and stem cell transplantation. These therapeutic regimens are well known to develop highly toxic and long-lasting side-effects including secondary cancers in the future lifespan of pediatric patients. Despite these intensive therapeutic regimens, cancer may still relapse as refractory and metastatic cancer. Therefore, further understanding the causes of different pediatric cancers, mechanisms of drug-resistance, and causes of relapse and metastasis is required for developing and advancing less toxic and more effective therapeutic strategies for pediatric cancers. Recent advancements in immunotherapies and targeted therapeutic approaches using pharmacological inhibitors are one step in this direction.In this Special Issue of Cancers, authors contributed original research and review articles focusing on different aspects of pediatric cancer development, causes, maintenance, and therapeutic strategies. The collected articles in this Special Issue will further enhance our knowledge and understanding of pediatric cancers and drive the development of novel therapeutic strategies.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
infections; cancer; children; bacteremia; pneumonia; sarcoma; solid tumor; outcome; KI67; EZRIN; 18F-FDG PET/CT; random forest; radiogenomics; chemotherapy response; metastasis; serine-threonine kinase receptor-associated protein; neuroblastoma; CRISPR-Cas9; neuroblastoma; metronomic chemotherapy; maintenance therapy; high-risk; Ewing sarcoma; RNA-binding proteins; regulation network; prognosis prediction; risk model; melanotic neuroectodermal tumor of infancy; inoperable; metastatic; recurrent; chemotherapy; adjuvant; neoadjuvant; systemic treatment; childhood malignant bone tumors; survivorship; late effects; somatic disease; cohort study; rhabdomyosarcoma; targeted therapies; cell surface proteomics; B7-H3; stress; allostasis; stress regulatory pathways; stress dysregulation; stress reactivity; early life stress; childhood cancer; cytotoxic cancer treatment; interventions; ependymoma; risk stratification; molecular group; prognosis; nephroblastoma; clinical malformations; cancer predisposition syndromes; tumor surveillance; outcome; n/a; DSRCT; EWSR1-WT1; preclinical model; in vitro model; pediatric cancer; sarcoma; pediatric; brain; tumor; medulloblastoma; glioma; ependymoma; natural products; Ewing sarcoma; drug discovery; fungal secondary metabolites; soil microbes; rhabdomyosarcoma; RH30; RD; EZH2; epigenetic; EPZ005687; DZNep; AdOx; malignant rhabdoid tumor; hepatoblastoma; small cell undifferentiated (SCUD) hepatoblastoma; SMARCB1; INI1; pediatric liver tumors; drug repurposing; PI3K pathway; epigenetics; Fimepinostat; neuroblastoma; pediatric cancer; LPAR1; neuroblastoma; LPA; tumor metastasis; bioinformatics analysis; neuroblastoma; ulixertinib; ERK inhibition; combination therapy; c-Myc/N-Myc; neuroblastoma; cell differentiation; ATRA; SOX4; diffuse intrinsic pontine glioma; immunotherapy; immune microenvironment; immune checkpoint inhibitor; vaccine; oncolytic virus; myeloid sarcoma; chloroma; acute myeloid leukemia; pediatric; chemotherapy; pediatric cancers; VIPN; DIC; MDR; drug transporters; childhood acute leukemia; early complication; hyperleukocytosis; risk factor; survival outcome; n/a